Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Signs DrugMatrix Deals with Lilly and FDA s Interdisciplinary Pharmacogenomic Review Group

NEW YORK, Nov. 17 (GenomeWeb News) - Iconix Pharmaceuticals has licensed its DrugMatrix chemogenomics system and Drug Signatures library to Elli Lilly and renewed a deal with the US Food and Drug Administration for the DrugMatrix system, the firm said today.

 

Under the agreement with Lilly, Iconix will add new compounds and tissues to DrugMatrix and identify additional Drug Signatures for those new domains. Lilly will integrate its in-house toxicogenomics data with DrugMatrix.

 

The agreement is similar to ones Iconix has in place with Bristol-Myers Squibb and Abbott.

 

Under the deal with the FDA, the agency's Center for Drug Evaluation and Research renewed its DrugMatrix agreement. The FDA installed DrugMatrix originally in March 2003 to use genomic markers to profile drug effects.

 

Under the renewal, Iconix will provide DrugMatrix to the FDA's Interdisciplinary Pharmacogenomic Review Group to evaluate genomic data submitted under the new data submission guidelines.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.